¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"È¿"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • curdling ferment
    ÀÀÀ¯¹ßÈ¿¼Ò
  • cytolytic ferment
    ¼¼Æ÷¿ëÇØ¹ßÈ¿¼Ò
  • cytopathic effect
    ¼¼Æ÷º´º¯È¿°ú
  • cytosolic enzyme
    ¼¼Æ÷¾×È¿¼Ò
  • carrier effect
    ¿î¹Ýüȿ°ú
  • carry-over effect
    ÀÜÈ¿
  • catalase
    °ú»êÈ­¼ö¼ÒºÐÇØÈ¿¼Ò, īŻ¶ó¾ÆÁ¦
  • cavitation effect
    °øµ¿È¿°ú
  • ceiling effect
    ÃÖ°íÈ¿°ú
  • chitinase
    ŰƾºÐÇØÈ¿¼Ò
  • cholesterol esterase
    ÄÝ·¹½ºÅ×·Ñ¿¡½ºÅ׸£ºÐÇØÈ¿¼Ò
  • choline acetyltransferase
    Äݸ°¾Æ¼¼Æ¿Àüȯȿ¼Ò
  • dehydrase
    Å»¼ö¼ÒÈ¿¼Ò
  • dehydratase
    Å»¼öÈ¿¼Ò
  • dehydrogenase
    Å»¼ö¼ÒÈ¿¼Ò
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • reverse transcriptase
    ¿ªÀü»çÈ¿¼Ò, ¿ªÀü»ç
  • uricase
    ¿ä»êºÐÇØÈ¿¼Ò
  • urease
    ¿ä¼ÒºÐÇØÈ¿¼Ò
  • validity
    Ÿ´ç¼º, È¿·Â, Ÿ´çµµ
  • effective blood volume
    À¯È¿Ç÷¾×·®
  • zymosis
    ¹ßÈ¿
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • cumulative effect
    ´©ÀûÈ¿°ú, ÃàÀûÈ¿°ú
  • curative effect
    Ä¡·áÈ¿°ú
  • curdling enzyme
    ÀÀÀ¯È¿¼Ò
  • curdling ferment
    ÀÀÀ¯¹ßÈ¿¼Ò
  • cytochrome oxidase test
    ½ÃÅäÅ©·Ò»êÈ­È¿¼Ò°Ë»ç
  • cytolytic ferment
    ¼¼Æ÷¿ëÇØ¹ßÈ¿¼Ò
  • cytopathic effect
    ¼¼Æ÷º´º¯È¿°ú
  • cytosolic enzyme
    ¼¼Æ÷ÁúÈ¿¼Ò
  • effective capacity
    À¯È¿¿ë·®
  • effective charge
    À¯È¿ÀüÇÏ
  • effective chlorine
    À¯È¿¿°¼Ò
  • effective current
    À¯È¿Àü·ù
  • efficient coitus
    À¯È¿¼º±³
  • isoeffect curve
    µîÈ¿°ú°î¼±
  • minimal effective analgesic concentration
    ÃÖ¼ÒÈ¿°úÁøÅë³óµµ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • Lactobacillus fermenti
    ¹ßÈ¿¶ôÆ®»ê°£±Õ.
  • Lactobacillus fermenti
    ¹ßÈ¿¶ôÆ®»ê°£±Õ.
  • Lipase
    Áö¹æºÐÇØÈ¿¼Ò(ò·Û¸ÝÂú°ý£áÈ), ¶óÀÌÆäÀÌÁî
  • Lipoprotein lipase
    Áö´Ü¹é(ò·Ó±ÛÜ) Áö¹æºÐÇØÈ¿¼Ò(ò·Û¸ÝÂú°ý£áÈ)
  • MAO inhibitor
    ¸ð³ë¾Æ¹Î»êÈ­È¿¼Ò ¾ïÁ¦Á¦.
  • MAO inhibitor
    ¸ð³ë¾Æ¹Î »êÈ­È¿¼Ò ÀúÇØÁ¦.
  • MAO inhibitor(MAOI)
    ´Ü°¡¾Æ¹Î»êÈ­È¿¼Ò¾ïÁ¦Á¦
  • MAO=> monoamine oxldase
    ¸ð³ë¾Æ¹Î»êÈ­È¿¼Ò.
  • MAO=£¾monoamine oxidase
    ¸ð³ë¾Æ¹Î»ê È­È¿¼Ò.
  • MAO=£¾monoamine oxldase
    ¸ð³ë¾Æ¹Î»ê È­È¿¼Ò.
  • MED=> minimum effective dose
    ÃÖ¼ÒÀ¯È¿·®.
  • MED=£¾minimum effective dose
    ÃÖ¼ÒÀ¯È¿·®.
  • NADH dehydrogenase
    NADH Å»¼ö¼ÒÈ¿¼Ò
  • NADH-methemoglobin reductase
    NADH-¸ÞÆ®Çì¸ð±Û·Îºó ȯ¿øÈ¿¼Ò
  • NADPH-dependent oxidase system
    NADPH-ÀÇÁ¸¼º »êÈ­È¿¼Ò°è
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • enzyme inhibition
    È¿¼Ò¾ïÁ¦.
  • enzyme-linked immunoelectrotransfer blot
    È¿¼Ò¿¬°ü ¸é¿ªÀü±âÀü´ÞÁ¡
  • enzyme-linked immunosorbent assay
    È¿¼Ò¿¬°ü¸é¿ªÈíÂø¹ý
  • ferment fever
    È¿¼Ò¿­(ý£áÈæð).
  • enzymotherapy
    È¿¼Ò¿ä¹ý.
  • zymogen
    È¿¼Ò¿ø(ý£áÈê«)
  • zymogen
    È¿¼Ò¿ø(ý£áÈê«)
  • zymogen
    È¿¼Ò¿ø(ý£áÈê«), ÀÚÀ̸ðƾ.
  • zymogen granule
    È¿¼Ò¿ø°ú¸³
  • zymogen granule
    È¿¼Ò¿ø°ú¸³(ý£áÈê« ÍýØ£)
  • zymogen droplet
    È¿¼Ò¿ø°ú¸³, È¿¿ø°ú¸³(ý£ê«Î¨í£)
  • zymogen droplet
    È¿¼Ò¿ø°ú¸³, È¿¿ø°ú¸³(ý£ê«Î¨í£).
  • zymogen granule
    È¿¼Ò¿ø°ú¸³, È¿¿ø°ú¸³(ý£ê«Î¨í£).
  • zymogenic cell
    È¿¼Ò¿ø¼¼Æ÷(ý£áÈê«á¬øà).
  • enzyme induction
    È¿¼ÒÀ¯µµ(ý£áÈë¯Óô).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • benzidine oxidase
    º¥Áöµò»êÈ­È¿¼Ò
  • beta (¥â)-lactamase
    º£Å¸¶ôŸ¸¶Á¦, º£Å¸¶ôŽ °¡¼öºÐÇØÈ¿¼Ò
  • beta-ARK : beta-adrenergic receptor kinase
    º£Å¸-¾Æµå·¹³¯¸°(¼º)¼ö¿ëü ÀλêÈ­È¿¼Ò.
  • beta-lactamase inhibitors
    º£Å¸-¶ôޯı«È¿¼Ò¾ïÁ¦Á¦.
  • binaural hearing (effect)
    ¾çÀÌû(È¿°ú)
  • binaural hearing (effect)
    ¾çÀÌû(È¿°ú).
  • bioavailability
    »ýü(³»)ÀÌ¿ë(È¿)À²(ßæô÷(Ò®)ì¦éÄ(üù)ëÒ), »ýü³»À¯¿ëµµ.
  • bioavailability
    »ýü(³»)ÀÌ¿ë(È¿)À²(ßæô÷Ò®ì¦éÄüùëÒ), »ýü³»À¯¿ë¼Ò.
  • bioeffect
    »ý¹°ÇÐÀû È¿°ú
  • bioeffects
    »ý¹°ÇÐÀû È¿°ú (ßæÚªùÊîÜ üùÍý)
  • biologic effect
    »ý¹°ÇÐÀû È¿°ú
  • biologic effects
    »ý¹°ÇÐÀû È¿°ú (ßæÚªùÊîÜ üùÍý)
  • biological effect
    »ý¹°ÇÐÀû È¿°ú
  • biological effectiveness
    [°áÇÙ,ÀÓº´,¹ÙÀÌ] »ý¹°ÇÐÀû È¿°ú (¡­üùÍý).
  • biological effectiveness
    ¾à ¸® ¹Ì»ý,±â»ý,³»°ú,°áÇÙ,ÀÓº´ ºñÀÌ »ý¹°ÇÐÀû È¿°ú (¡­üùÍý).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • dispensable enzyme
    ºñÇʼö È¿¼Ò(Þªù±âÎý£áÈ) (ÔÒ) nonessential enzyme
  • dispersion effect
    "ºÐ»ê È¿°ú(ÝÂߤüùÍý), (ÔÒ) dispersion forces"
  • DNA-relaxing enzyme
    DNAÀÌ¿Ï È¿¼Ò(ì¬èÐý£áÈ) (ÔÒ) topoisomerase
  • DNA restriction enzyme
    DNA Á¦ÇÑ È¿¼Ò(ð¤ùÚý£áÈ) (ÔÒ) restriction enzyme
  • Dorn effect
    "µ· È¿°ú(üùÍý), (ÔÒ) sedimentation potential"
  • drag effect
    ²ø¸² È¿°ú(üùÍý) (ÔÒ) solvent drag
  • drug-detoxication enzyme
    ¾à¹°Çص¶ È¿¼Ò(å·Úªú°Ô¸ý£áÈ) (ÔÒ) drug-metabolizing enzyme
  • drug-metbolizing enzyme
    ¾à¹°´ë»ç È¿¼Ò(å·ÚªÓÛÞóý£áÈ)
  • dual-effect mutant
    ÀÌÁßÈ¿°ú º¯ÀÌü(ì£ñìüùÍýܨì¶ô÷)
  • early enzyme
    Á¶±â È¿¼Ò(ðÄÑ¢ý£áÈ)
  • ectoenzyme
    ¿¢ÅäÈ¿¼Ò(ý£áÈ)
  • effective concentration
    À¯È¿ ³óµµ (êóüùÒØÓø)
  • effective half-life
    À¯È¿ ¹Ý°¨±â(êóüùÚâÊõÑ¢)
  • effective lethal phase
    À¯È¿ Ä¡»ç±â(êóüùöÈÞÝÑ¢)
  • effector
    "ÀÛµ¿ÀÚ(íÂÔÑí­), È¿°úÀÚ(üùÍýí­)"
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
  • T50.1
    Loop [high-ceiling] diuretics
    °í¸®[°íÈ¿´É]ÀÌ´¢Á¦
  • T50.2
    Carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics
    ź»êÅ»¼öÈ¿¼Ò ¾ïÁ¦Á¦, º¥Á¶Å¸À̾ƴÙÀ̾ÆÀÚÀÌµå ¹× ±âŸ ÀÌ´¢Á¦
  • T52
    Toxic effect of organic solvents
    À¯±â¿ëÁ¦ÀÇ Áßµ¶È¿°ú
  • Y43.6
    Enzymes, NEC
    ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº È¿¼Ò·ù
  • Y52.4
    Angiotensin-converting-enzyme inhibitors
    ¾ÈÁö¿ÀÅٽŠÀüȯȿ¼Ò ¾ïÁ¦¾à¹°
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • effective blood volume
    À¯È¿ Ç÷¾×·®
  • effective diameter
    À¯È¿ Áö¸§
  • effective dose 50%
    Áß°£ À¯È¿·®, 50% À¯È¿·®
    µ¿¹°¿¡ µ¶¼Ò³ª ¾à¹° Åõ¿© ½Ã, 50%ÀÇ µ¿¹°¿¡¼­ À¯È¿ÇÏ´Ù°í ÃßÁ¤µÇ´Â ¿ë·®.
  • effective focal spot
    ½ÇÈ¿ ÃÊÁ¡
  • effective mass
    À¯È¿ Áú·®
  • effective osmolality
    À¯È¿ »ïÅõÁú ³óµµ
  • effective ratio
    À¯È¿À²
    ¾î´À ÇѰè±îÁö´Â ¾àÁ¦ ¿ë·®°ú À¯È¿À²Àº ºñ·ÊÇÑ´Ù. ÇѰè À̻󿡼­´Â ºÎÀÛ¿ëÀÌ ³ªÅ¸³­´Ù.
  • effective tonicity
    À¯È¿ Àå·Â
  • effective weight
    À¯È¿ Áß·®
  • effector
    È¿°ú±â, È¿°úü, ÁÖÈ¿ ÀÎÀÚ, ÀÛµ¿ ¹°Áú, ÁÖÈ¿ ±â°ü
    ½Å°æ Ãæµ¿À» Á÷Á¢ ¼ö¿ëÇÏ¿© ¹ÝÀÀÇÏ´Â ±ÙÀ̳ª ¼±ÀÇ ÀÏÁ¤ ºÎºÐ.
  • effector-inhibitory factor
    È¿°ú±â ¾ïÁ¦ ÀÎÀÚ
  • efferent effect
    ¿ø½É È¿°ú
  • efficacy
    È¿´É
    °á°ú¸¦ À¯µµÇÏ´Â ¾àÁ¦³ª Ä¡·áÀÇ ´É·Â.
  • efficiency of ablation per pulse
    ÆÞ½º´ç Á¦°Å È¿À²
  • efficient
    È¿°úÀûÀÎ, È¿À²ÀûÀÎ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • allostery
    ¾Ë·Î½ºÅ׸¯ È¿°ú 6
  • altogether
    ¾ÆÁÖÀüÇô;ÀüºÎÇØ¼­;´ëü·Î-ÀüüÀû È¿°ú )
  • annul
    ¹«È¿·ÎÇÏ´Ù;Ãë¼ÒÇÏ´Ù
  • annulment
    Ãë¼Ò;½ÇÈ¿;ÆóÁö;(È¥ÀÎÀÇ)¹«È¿ ¼±¾ð
  • antidotal
    ÇØµ¶Á¦ÀÇ;ÇØµ¶ÀÇ(È¿ÇèÀÌ ÀÖ´Â)
  • antiinflammatoru
    ¿°Áõ¿¡ È¿ÇèÀÌ ÀÖ´Â;Ç׿°ÁõÀÇ;Ç׿°Áõ¾à
  • antipsychotic
    Á¤½Åº´¿¡ È¿Çè ÀÖ´Â;Á¤½Åº´ Ä¡·á¾à;Ç×Á¤½Åº´¾à
  • apoenzyme
    ¾ÖÆ÷ È¿¼Ò
  • aposematic
    (ü»ö µîÀÌ ¹æ¾î È¿°ú°¡ ÀÖ´Â)°æ°è(»ö)ÀÇ
  • arginase
    ¾Æ¸£±â³ª¾ÆÁ¦(¾Æ¸£±â´ÑÀ» ¿ä¼Ò·Î ºÐÇØÇÏ´Â È¿¼Ò)
  • avail
    µµ¿òÀ̵ǴÙ;¼Ò¿ëÀ̵ǴÙ;ÀÌ·Ó´Ù;ÀÌÀÍ;È¿¿ë
  • availability
    À¯È¿;À¯ÀÍ;µµ¿ò;¾µ¸ð 
  • available
    ÀÌ¿ëÇÒ ¼ö ÀÖ´Â;¼Õ¿¡³ÖÀ»¼öÀÖ´Â;Àü½ÉÇÒ¼öÀÖ´Â;¿©°¡°¡ÀÖ´Â;À¯È¿ÇÑ
  • avoidance
    µµÇÇ;ȸÇÇ;¹«È¿
  • background
    ¹è°æ;¹ÙÅÁ»ö;¼Ò¾ç;À½¾ÇÈ¿°ú
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
ÅëÇÕ°Ë»ö ¿Ï·á